Literature DB >> 30404752

Data Linking Diabetes Mellitus and Atrial Fibrillation-How Strong Is the Evidence? From Epidemiology and Pathophysiology to Therapeutic Implications.

Răzvan C Şerban1, Alina Scridon2.   

Abstract

According to estimates, around 5% of the world population has hazel eyes. And there are about as many people with diabetes mellitus (DM). Red hair occurs naturally in up to 2% of the human population. And about as many people are estimated to have atrial fibrillation (AF). If a hazel eyed person with red hair does not surprise us, should a diabetic patient with AF? Accumulating epidemiologic data suggest, however, that the DM-AF association may be more than a simple coincidence. But, how strong is this evidence? Experimental studies bring evidence for a DM-induced atrial proarrhythmic remodelling. But how relevant are these data for the clinical setting? In this review, we aim to provide a critical analysis of the existing clinical and experimental, epidemiologic, and mechanistic data that bridge DM and AF, we emphasize a number of questions that remain to be answered, and we identify hotspots for future research. The therapeutic implications of the DM-AF coexistence are also discussed, with a focus on rhythm control and on conventional and DM-specific upstream therapies for AF management.
Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30404752     DOI: 10.1016/j.cjca.2018.08.018

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  8 in total

Review 1.  Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.

Authors:  Ting-Wei Lee; Ting-I Lee; Yung-Kuo Lin; Yao-Chang Chen; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Cell Mol Life Sci       Date:  2020-09-23       Impact factor: 9.261

2.  MiR-21-3p Inhibits Adipose Browning by Targeting FGFR1 and Aggravates Atrial Fibrosis in Diabetes.

Authors:  Jian-An Pan; Hao Lin; Jian-Ying Yu; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang; Jun Gu
Journal:  Oxid Med Cell Longev       Date:  2021-08-25       Impact factor: 6.543

Review 3.  Obstructive Sleep Apnea and Atrial Fibrillation.

Authors:  Amalia Ioanna Moula; Iris Parrini; Cecilia Tetta; Fabiana Lucà; Gianmarco Parise; Carmelo Massimiliano Rao; Emanuela Mauro; Orlando Parise; Francesco Matteucci; Michele Massimo Gulizia; Mark La Meir; Sandro Gelsomino
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

Review 4.  Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?

Authors:  Alina Scridon; Alkora Ioana Balan
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

5.  Comparison of New-Onset Diabetes Mellitus among Patients with Atrial Fibrillation or Atrial Flutter.

Authors:  Wei Syun Hu; Cheng Li Lin
Journal:  Korean Circ J       Date:  2020-03-13       Impact factor: 3.243

6.  Diabetes Mellitus Promotes Atrial Structural Remodeling and PARP-1/Ikkα/NF-κB Pathway Activation in Mice.

Authors:  Tianyu Meng; Jie Wang; Manyun Tang; Shangyu Liu; Ligang Ding; Yang Yan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-17       Impact factor: 3.168

7.  Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study.

Authors:  Jakub Gumprecht; Gregory Y H Lip; Adam Sokal; Beata Średniawa; Katarzyna Mitręga; Jakub Stokwiszewski; Łukasz Wierucki; Aleksandra Rajca; Marcin Rutkowski; Tomasz Zdrojewski; Tomasz Grodzicki; Jarosław Kaźmierczak; Grzegorz Opolski; Zbigniew Kalarus
Journal:  Cardiovasc Diabetol       Date:  2021-06-24       Impact factor: 9.951

8.  Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus.

Authors:  Jung-Chi Hsu; Yen-Yun Yang; Shu-Lin Chuang; Chih-Chieh Yu; Lian-Yu Lin
Journal:  Cardiovasc Diabetol       Date:  2021-07-23       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.